Ceregene Initiates A New Controlled Phase 2b Trial Of CERE-120 For Parkinson’s Disease

SAN DIEGO, Oct. 19 /PRNewswire
http://www.dailymarkets.com/stock/20...nsons-disease/

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson’s disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons.

Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).


The first Phase II trial began recruiting in 2007. Per Ceregene, that trial did not meet the anticipated endpoints.
So, this "new" Phase I/II trial is now recruiting; putamen only. The brain target in the first trial is not the same as the brain target in this new trial; both substantia nigra and putamen.